FDA Floats Broader Pathway For Nicotine Replacement Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s report to Congress on tobacco abstinence therapy points toward a “comprehensive strategy” for tobacco and nicotine product regulation, incorporating the work of the drug, device and tobacco centers. Some smoking cessation experts say changes are overdue.
You may also be interested in...
US Has Pieces For Solving Policy Puzzle To Spur Spread Of Smoking Cessation Products, Programs
Former FDA tobacco programs chief Mitch Zeller says needed is commitment from White House to require reduction in nicotine levels in tobacco products and movement by FDA on finalizing rules prohibiting use of menthol and other flavors in cigarettes and some cigars.
U.K. Packages All Electronic Cigarettes Under Medical Regulation
The U.K. pharma regulator requires all electronic cigarettes to be licensed as nonprescription medicines beginning in 2016, noting concerns about product quality. Meanwhile, FDA considers allowing e-cigarettes to be marketed as nicotine replacement therapy on a case-by-case basis.
Smoking Cessation Label Changes Could Lay Groundwork For Indications
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.